In 2004, a lymphogranuloma venereum (LGV) epidemic among men who have sex with men in the Netherlands motivated the introduction of enhanced surveillance. We evaluated the acceptability of the enhanced LGV surveillance in the Netherlands in 2004-2005 to provide recommendations for future surveillance. Completeness of requested patient information was analysed. All 12 sexually transmitted infection (STI) health services participating in the 2004-2005 STI surveillance completed evaluation questionnaires and rated surveillance system features from 1="very poor" to 5="very good". Information from enhanced LGV surveillance was available for 34 (33%) of 104 cases. For these 34 cases, median proportions of response decreased successively for clinical information (100%), sexual anamnesis (71%) and details about the last sex partners (44%). A median score of 4 ("good") was assigned to simplicity, required resources and surveillance information requested and distributed. Seven respondents favoured continuation of LGV surveillance, whereof six preferred modifications, usually meaning less extensive surveillance. In conclusion, the enhanced LGV surveillance was generally regarded as adequate. However, it was limited by low completeness, underlining the need to keep requested information to a minimum. The routine STI surveillance now includes LGV diagnosis and, following this evaluation, the additional enhanced surveillance was discontinued. However, occasional cases justify alertness and LGV remains under routine STI surveillance in the Netherlands.
Download full-text PDF |
Source |
---|
Sex Transm Dis
December 2024
Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland.
Background: Infection with Chlamydia trachomatis (CT) can have distinct clinical presentations, such as trachoma, or lymphogranuloma venereum (LGV). Certain populations are at greater risk for LGV acquisition and transmission, which requires a longer duration of therapy than other urogenital CT sexually transmitted infections (STIs). Commercial assays are not available in the United States to distinguish LGV from non-LGV serovars.
View Article and Find Full Text PDFSex Transm Infect
September 2024
National Reference Laboratory (NRL) for Sexually Transmitted Infections (STI), Department of Infectious Diseases, National Institute of Health (Instituto Nacional de Saúde Doutor Ricardo Jorge, INSA, IP), Lisboa, Lisboa, Portugal
Microorganisms
June 2024
Public Health National Program Office, Department of Veterans Affairs, Washington, DC 20420, USA.
Sex Transm Infect
November 2024
Sexually Transmitted Infections Study Group (GEITS), Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Madrid, Spain
Euro Surveill
May 2024
Members of the Anachla study group are listed under Acknowledgements.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!